OpGen (NASDAQ: OPGN) is one of 185 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare OpGen to related businesses based on the strength of its analyst recommendations, dividends, risk, earnings, institutional ownership, profitability and valuation.
This table compares OpGen and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and price targets for OpGen and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
OpGen currently has a consensus price target of $1.00, indicating a potential upside of 426.32%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.61%. Given OpGen’s stronger consensus rating and higher possible upside, analysts clearly believe OpGen is more favorable than its competitors.
Earnings and Valuation
This table compares OpGen and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|OpGen||$4.03 million||-$19.16 million||-0.37|
|OpGen Competitors||$217.40 million||-$39.40 million||-82.97|
OpGen’s competitors have higher revenue, but lower earnings than OpGen. OpGen is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
11.8% of OpGen shares are held by institutional investors. Comparatively, 49.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 17.4% of OpGen shares are held by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
OpGen beats its competitors on 7 of the 12 factors compared.
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.